Searched over 200M research papers
10 papers analyzed
These studies suggest that metoprolol can effectively lower heart rate in various patient populations, including those with myocardial infarction, chronic heart failure, and dilated cardiomyopathy.
5 papers analyzed
20 papers analyzed
Metoprolol, a beta-blocker, is widely used to manage various cardiovascular conditions by reducing heart rate and blood pressure. This article synthesizes research findings on the effectiveness of metoprolol in lowering heart rate across different patient populations and conditions.
In patients with acute myocardial infarction and a heart rate of 65 beats per minute or less, metoprolol significantly reduced heart rate, cardiac index, rate pressure product, and stroke work index by 10-20% compared to placebo. This reduction was most pronounced immediately after metoprolol administration, indicating its rapid effect on heart rate control.
A study comparing immediate-release (IR) and controlled-release/extended-release (CR/XL) formulations of metoprolol in heart failure patients found that higher doses of CR/XL (200 mg) were more effective in reducing heart rate than lower doses or IR formulations. This suggests that the formulation and dosage of metoprolol play crucial roles in its effectiveness in heart rate reduction.
In patients with moderate to severe asymptomatic aortic valve stenosis, metoprolol significantly decreased heart rate by an average of 8 beats per minute compared to placebo. This reduction was associated with improved hemodynamic parameters, such as increased ejection time and reduced aortic valve gradients, indicating beneficial effects beyond heart rate control.
Metoprolol has been shown to effectively reduce heart rate in chronic heart failure patients. A study involving Chinese patients with heart rates above 80 bpm demonstrated significant reductions in heart rate over a 12-month period, with associated improvements in cardiac performance and motor function. This highlights the long-term benefits of metoprolol in managing heart rate in chronic heart failure.
Research indicates that women may experience a more pronounced reduction in heart rate and a higher risk of bradycardia at higher metoprolol plasma concentrations compared to men. This suggests the need for sex-specific considerations when prescribing metoprolol to optimize heart rate control and minimize adverse effects.
The metabolism of metoprolol is significantly influenced by the CYP2D6 enzyme. Patients with poor CYP2D6 metabolism exhibited lower heart rates and a higher incidence of bradycardia compared to normal metabolizers. This underscores the importance of genetic testing in personalizing metoprolol therapy to achieve optimal heart rate control.
In a study comparing metoprolol with sotalol for heart rate control in patients with chronic atrial fibrillation, both drugs effectively reduced heart rate. However, sotalol was superior to metoprolol at submaximal exercise levels, suggesting that while metoprolol is effective, other beta-blockers may offer better control in specific scenarios.
Metoprolol is effective in lowering heart rate across various cardiovascular conditions, including acute myocardial infarction, chronic heart failure, and asymptomatic aortic valve stenosis. Its efficacy is influenced by dosage, formulation, sex, and genetic factors. Personalized approaches considering these variables can optimize heart rate control and improve patient outcomes.
Most relevant research papers on this topic